Imunon, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Imunon, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $110.00, a 79.25% decline year-over-year.
- Imunon, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $0.00.
- Imunon, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $11.00.
- Imunon, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-12-31 was $63.00.
- Imunon, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $595.00.
- Imunon, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $4.72K, a 98.73% decline from fiscal 2020.
- Imunon, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $371.89K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-09-30 | $110.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $184.00 derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $604.00 derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | $11.00 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $63.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $595.00 10-K · filed 2024-03-28 |
| 2023-09-30 | $530.00 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $4.72K 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $4.72K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $4.72K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $4.72K 10-Q · filed 2022-05-16 | $376.62K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $371.89K 10-K · filed 2022-03-31 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | |
| 2020-06-30 | $371.89K 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |